ClearBridge Investments released its “ClearBridge All Cap Growth Strategy” second-quarter 2025 investor letter, noting growth stocks led the stock market rebound, with the Russell 3000 Growth Index rising 17.6%. The Strategy, however, underperformed its benchmark. Check the fund’s top five holdings for insights on its picks in 2025.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a biotech company focused on cystic fibrosis therapies, saw a one-month return of -17.20% and shares losing 21.15% over 52 weeks. On August 29, 2025, VRTX stock closed at $391.02 per share, with a market cap of $100.254 billion. ClearBridge All Cap Growth Strategy provided insights on VRTX in its investor letter.

Despite revenue growth in Q2 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) isn’t among the 30 most popular stocks among hedge funds. The company delivered $2.96 billion in revenue, with 53 hedge fund portfolios holding VRTX shares at the end of the second quarter. While VRTX shows potential, certain AI stocks may offer greater upside with less downside risk.

Read more at Yahoo Finance: Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings